Initial Statement of Beneficial Ownership (3)
March 30 2020 - 06:26PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
McKew John C. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/18/2020
|
3. Issuer Name and Ticker or Trading Symbol
LUMOS PHARMA, INC. [(LUMO)]
|
(Last)
(First)
(Middle)
4200 MARATHON BLVD, SUITE 200 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Scientific Officer / |
(Street)
AUSTIN, TX 78756
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | 3/4/2017 (1) | 7/11/2026 | Common Stock | 81690.0 | $4.82 | D | |
Stock Option (Right to Buy) | 12/5/2018 (2) | 1/18/2028 | Common Stock | 9583.0 | $2.45 | D | |
Stock Option (Right to Buy) | 8/29/2018 (3) | 8/29/2028 | Common Stock | 6541.0 | $2.45 | D | |
Explanation of Responses: |
(1) | The shares subject to the option became fully vested and exercisable March 4, 2020. |
(2) | One-fourth of the shares subject to the option vested and became exercisable on December 5, 2018, and thereafter the remainder of the shares subject to the option continue to vest in 36 substantially equal monthly installments, subject to the reporting person's continued service with the Issuer and subject to acceleration upon the occurrence of certain events. |
(3) | The shares subject to the option became fully vested and exercisable on the grant date, August 29, 2018. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
McKew John C. 4200 MARATHON BLVD SUITE 200 AUSTIN, TX 78756 |
|
| Chief Scientific Officer |
|
Signatures
|
/s/ Ryan Trytten, attorney-in-fact | | 3/30/2020 |
**Signature of Reporting Person | Date |
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Feb 2024 to Mar 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2023 to Mar 2024